Open access · CC-BY
via OpenAlex
A Novel Mitophagy Assay for Skeletal Myotubes
Open access Journal of Neurology & Neurosurgery · 2017 · ▲ 3 citations
Deregulated nutrient-sensing
Mitochondrial dysfunction
Disabled macroautophagy
Cell culture / in vitro
Human
In vitro
Review
Abstract
We developed a simple ELISA technique as a quantitative in vitro assay for mitophagy in post mitotic skeletal muscle cells.We labeled the mitochondrial DNA of C2C12 myotubes cells by allowing incorporation of the thymidine analogue bromodeoxyuridine (BrdU) and following the decay of the label with time under basal and stimulated conditions.BrdU was incorporated into differentiated C2C12 myotubes at significant levels only after pharmacological treatment was used to increase the rate of mtDNA synthesis.PGC1α transduction, stimulation of AMPK, or inhibition of ERK1/2, all previously reported to increase the rate of mtDNA synthesis, induced BrdU incorporation at 4-10 fold over background during a 2 hour incorporation period.Using AMPK stimulation to stimulate initial DNA labeling we confirmed by both microscopy and cytometry methods that BrdU was incorporated into mitochondria and not into nuclei.After removal of the BrdU, the level of label in cells declined to approximately 25% by 24 hours and returned to background levels by 48 hours.The membrane depolariser carbonyl cyanide m-chlorophenyl hydrazone (CCCP; (10um) accelerated this decline, such that at 6 hours BrdU signal was reduced by 70-100%.24 or 48 hours of pretreatment with bafilomycin, a pharmacological inhibitor of early endosome acidification, partially reversed the CCCP stimulated loss of BrdU, and we confirmed by confocal microscopy that the BrdU in bafilomycin treated cells localized with LC3, a marker of early endosomes.Finally, we showed that treatment with urolithin, previously reported to inhibit mitophagy at high concentrations, showed a dose responsive inhibition of BrdU signal loss with a maximum of about 50% at 50uM.This assay represents a robust and simple method to evaluate agents accelerating mitophagy in postmitotic cells.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.19080/oajnn.2017.04.555649
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Webb, M. (2017). A Novel Mitophagy Assay for Skeletal Myotubes. <em>Open access Journal of Neurology & Neurosurgery</em>. https://doi.org/10.19080/oajnn.2017.04.555649
Vancouver
Webb M. A Novel Mitophagy Assay for Skeletal Myotubes. Open access Journal of Neurology & Neurosurgery. 2017. doi:10.19080/oajnn.2017.04.555649.
BibTeX
@article{michael2017ANovel,
title = {A Novel Mitophagy Assay for Skeletal Myotubes},
author = {Michael Webb},
journal = {Open access Journal of Neurology & Neurosurgery},
year = {2017},
doi = {10.19080/oajnn.2017.04.555649},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Scientific Reports 2015
Open access · CC-BY
Resveratrol Treatment after Status Epilepticus Restrains Neurodegeneration and Abnormal Neurogenesis with Suppression of Oxidative Stress and Inflammation
Aging and Disease 2020
Open access · CC-BY
Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
Research Square 2022
Preprint · CC-BY
Nicotinamide mononucleotide enhances the efficacy and persistence of CD19 CAR-T cells via NAD + –Sirt1 axis
Biomolecules 2020
Open access · CC-BY
Extracellular Vesicles from Healthy Cells Improves Cell Function and Stemness in Premature Senescent Stem Cells by miR-302b and HIF-1α Activation
Signal Transduction and Targeted Therapy 2020
Open access · CC-BY
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial
Stem Cells 2010
Preprint · CC-BY